KRAS and non-small cell lung carcinoma: A meta-analysis was conducted to evaluate the association between KRAS mutation status and progression-free survival (PFS) in patients with non-small-cell lung cancer (NSCLC) receiving first-line immune checkpoint inhibitor monotherapy.